Takeda starts clinical trial of Novavax COVID-19 vaccine in Japan

Takeda Pharmaceutical Co. said Wednesday it has started a clinical trial of a COVID-19 vaccine developed by U.S. biotechnology firm Novavax Inc. in Japan, planning to domestically produce and supply it in the second half of 2021.The Japanese drugmaker said it expects to gain results from a study on 200 Japanese participants aged 20 or older in the second half of this year.The company is capable of producing over 250 million doses of the vaccine, it said.Related coverage:COVID vaccine for elderly to be distributed based on populationMalaysian PM launches nationwide COVID-19 vaccine driveREAD FULL ARTICLE